| | | Autonomous PD () | Assisted PD () |
| | Age (years) | 55,7 ± 15,2 | 58 ± 20 |
| | Male (/%) | 122 (66,67) | 9 (52,94) |
| | Hypertension (/%) | 172 (93,99) | 12 (70,59) |
| | Diabetes (/%) | 58 (31,69) | 6 (35,29) |
| | APD (/%) | 64 (34,97) | 7 (41,18) |
| | CAPD (/%) | 119 (65,03) | 10 (58,82) |
| | Time under PD (months) | 29,7 ± 22,7 | 36,98 ± 31,43 |
| | Technique survival (months/%) | 12 m | 91,9 | 12 m | 92,3 | | 24 m | 81,7 | 24 m | 92,3 | | 36 m | 72,1 | 36 m | 83,1 | | 48 m | 68,3 | 48 m | 72,7 |
| | Patient survival (months/%) | 12 m | 95,9 | 12 m | 93,3 | | 24 m | 93,7 | 24 m | 93,3 | | 36 m | 89 | 36 m | 93,3 | | 48 m | 82 | 48 m | 74,7 |
| | Weekly kt/V | 2,4 ± 0,70 | 2,22 ± 0,60 |
| | nPCR (g/Kg/day) | 0,93 | 0,88 ± 0,30 |
| | PET | | D/P < 0,5 = 2% | | D/P 0,5–0,64 = 8 | | D/P 0,5–0,64 = 35% | | D/P 0,65–0,81 = 62% | D/P 0,65–0,81 = 6 | | D/P > 0,81 = 1% |
| | Residual renal function (mL/min/1,73 m2) | | 7,14 ± 11 | | 3,02 ± 3,85 |
|
|
